http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Tandem Diabetes Care Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers
-
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
TNDM DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – TNDM
-
Tandem Diabetes (TNDM) Appoints Mark Novara as EVP and Chief Commercial Officer
-
Tandem Diabetes Care Appoints Mark Novara as EVP and Chief Commercial Officer
-
Tandem Diabetes Care Announces Third Quarter 2023 Financial Results
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – TNDM
-
Tandem Diabetes Care to Announce Third Quarter 2023 Financial Results on November 1, 2023
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TNDM
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TNDM
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
Tandem Diabetes Care Announces Technology Access Program to Provide Customers with Purchase Pathway to the Tandem Mobi System
-
Tandem Diabetes Care Announces Second Quarter 2023 Financial Results and Updated Full Year 2023 Financial Guidance
-
Tandem Diabetes Care to Present at the UBS MedTech, Tools and Genomics Summit 2023
-
Tandem Diabetes (TNDM) Granted FDA Clearance for Tandem Mobi
-
Tandem Mobi, World’s Smallest Durable Insulin Delivery System, Receives FDA Clearance
-
Tandem Diabetes Care to Announce Second Quarter 2023 Financial Results on August 3, 2023
-
Tandem Diabetes Care to Present at the Jefferies Healthcare Conference
-
Tandem Diabetes Care Announces First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Guidance
-
Tandem Diabetes Care to Present at the BofA Securities 2023 Health Care Conference
-
Tandem Diabetes (TNDM) Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes
-
Tandem Diabetes Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes
-
Tandem Diabetes Care to Announce First Quarter 2023 Financial Results on May 3, 2023
-
Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology
-
Tandem Diabetes (TNDM) Appoints Rebecca Robertson as Board Chair
-
Tandem Diabetes Care Appoints New Chair of Board of Directors
-
Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical
-
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
-
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook
-
Tandem Diabetes Care to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Tandem Diabetes (TNDM) to acquire insulin patch pump developer AMF Medical
-
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical
-
Tandem Diabetes Care Earns Great Place to Work Certification™
-
Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology
-
Tandem Diabetes Care Announces Upcoming Conference Presentation
-
Tandem Diabetes Care Announces Third Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
Tandem Diabetes Care to Announce Third Quarter 2022 Financial Results on November 2, 2022
-
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
-
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:connect Mobile App
-
Tandem Diabetes Care Announces Second Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance
-
Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical
-
Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022
-
Tandem Diabetes (TNDM) Care Welcomes Two New Members to Board of Directors
-
Tandem Diabetes Care Welcomes Two New Members to Board of Directors

